{"id":"canagliflozin-ta-7284","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Genital mycotic infections"},{"rate":"8-12","effect":"Urinary tract infections"},{"rate":"5-10","effect":"Polyuria"},{"rate":"3-8","effect":"Thirst"},{"rate":"0.1-0.5","effect":"Diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL2048484","moleculeType":"Small molecule","molecularWeight":"444.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SGLT2 is responsible for reabsorbing filtered glucose in the proximal tubule of the nephron. By blocking this transporter, canagliflozin prevents glucose from being reabsorbed back into the bloodstream, allowing excess glucose to be excreted in the urine. This mechanism is independent of insulin secretion or action, making it effective across different stages of type 2 diabetes.","oneSentence":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:16.202Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01512849","phase":"PHASE1","title":"A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01387737","phase":"PHASE3","title":"Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1299},{"nctId":"NCT02220920","phase":"PHASE4","title":"Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":146},{"nctId":"NCT02227849","phase":"PHASE4","title":"Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":71},{"nctId":"NCT01022112","phase":"PHASE2","title":"An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":383},{"nctId":"NCT01413204","phase":"PHASE3","title":"Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2011-07","conditions":"Type 2 Diabetes Mellitus","enrollment":272},{"nctId":"NCT02622113","phase":"PHASE4","title":"Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":139},{"nctId":"NCT03436693","phase":"PHASE3","title":"Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-02-15","conditions":"Diabetic Nephropathy","enrollment":308},{"nctId":"NCT02220907","phase":"PHASE3","title":"Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":153},{"nctId":"NCT02354235","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":138},{"nctId":"NCT02354222","phase":"PHASE3","title":"Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2015-01","conditions":"Type 2 Diabetes Mellitus","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Canagliflozin (TA-7284)","genericName":"Canagliflozin (TA-7284)","companyName":"Tanabe Pharma Corporation","companyId":"tanabe-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}